Founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level.

For further information, please visit: www.clarusventures.com.

Wellington Partners ranks among the most successful pan-European venture capital firms. With more than €500 million under management, the firm invests into opportunities throughout Europe that have the potential to become global leaders, mainly in the areas of Information Technology, Media Convergence and Life Sciences. Since 1991, Wellington has established a worldwide network to aid its entrepreneurs in building companies on a global scale. Wellington Partners has invested in more than 100 companies in Europe and Israel, including publicly traded Actelion, Wavelight and XING, successful privately held companies like Alando (acquired by eBay) and Grandis (acquired by Novartis) as well as current portfolio companies like Immatics, MTM laboratories and Trigen.

For further information, please visit: www.wellington-partners.com.

DFJ Esprit is a venture capital fund backing extraordinary entrepreneurs and management teams in dynamic markets. DFJ Esprit invests in technology, new media, telecoms and healthcare businesses.

With over 130 years of investing experience between its partners and over 130 investments made, DFJ Esprit has one of the most experienced teams and longest track records in European venture capital.

DFJ Esprit has helped build some of the most successful European venture-backed businesses of recent years. These recent successes include KVS, Alphamosaic, Fillfactory, DNA Research Innovations, BlackSpider and Neteconomy. DFJ Esprit's partners have also been responsible for investments in companies including Virata, Cambridge Silicon Radio (CSR plc), Bookham, Microcosm and Xaar.

DFJ Esprit is part of the Draper Fisher Jurvetson (DFJ) Global Network with 120 investment professionals in more than 30 cities around the world. In the last twenty years the DFJ Network has backed over 300 companies including Hotmail, Baidu and Skype.

For further information, please visit: www.dfjesprit.com

Dow Chemical has committed over $400 million to its corporate venture capital investment programme. The company invests in venture capital funds focused on early-stage technology covering North America, Europe and Japan and makes direct investments in a wide range of young technology companies. Driven primarily by financial returns, Dow corporate venture capital is seeking to add value to portfolio companies through its expertise in science and technology, market knowledge and positioning, global presence and the Dow corporate brand equity.

SPARK Ventures is the leading quoted early-stage venture capital company in Europe. It manages over £240 million on behalf of major institutional investors, leading UK universities, and three quoted venture capital trusts. SPARK invests in entrepreneurs to create dynamic businesses in the technology, media, telecoms and healthcare & life sciences sectors. As well as capital, it brings a wealth of experience of developing high growth companies from early stage through to IPO or trade sale, adding value to its investments through active support and strategic direction.

For further information, please visit: www.sparkventures.com.

Top Technology Ventures is a London-based venture capital team making equity investments in UK technology companies. Since 1986 the team has invested in more than 90 small technology businesses with global market potential. In 2004 Top Technology Ventures became a part of the IP2IPO Group, combining Top Technology's early stage investing expertise with IP2IPO's proven ability to create new ventures based on world leading university IP.

NLV Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group.

For further information, visit www.nlvpartners.com.

Kaiser Permanente Ventures, the corporate venture capital arm of Kaiser Permanente, makes investments in medical devices, healthcare services and information technology companies. Kaiser Permanente Ventures is dedicated to partnering with entrepreneurial companies to build innovative and enduring businesses that advance the quality and affordability of health care. Since its inception in 1997, Kaiser Permanente Ventures has invested in more than 25 venture-capital backed companies at all stages of development, and contributed organizational expertise, time and resources to the success of these companies.

For additional information please visit www.kpventures.com.